A new breakthrough from the University of Saskatchewan might shorten the labor-intensive calving season for beef producers. Cetrorelix, a hormone drug commonly used in human IVF, has shown promising results in cattle in research conducted at the university. Dr. Jaswant Singh, along with graduate students Dylan Farmer and Carlos Leonardi, discovered the drug’s effectiveness in synchronizing ovulation in cows, leading to a more concentrated calving period.
Dr. Singh expressed excitement about the potential of Cetrorelix in reducing labor costs and improving animal management by streamlining the calving process. The drug’s ability to induce simultaneous pregnancies in cows could result in calves being born closer together, leading to benefits such as higher weaning weights and increased profitability for farmers.
Garner Deobald, a beef rancher and marketing manager at BoviGen Genetic Services, welcomed the potential of Cetrorelix as a valuable tool in cattle breeding. He emphasized the importance of exploring new methods that can enhance genetic selection and provide more accurate information on calf characteristics.
With the university applying for a patent on the drug, there is optimism that Cetrorelix could revolutionize artificial insemination practices in the cattle industry. Dr. Singh is optimistic about the drug’s prospects and envisions its adoption not only in Saskatchewan but globally, potentially transforming breeding practices and benefiting livestock producers worldwide.